Description

Simple

Clinical

Overview

Pharmacology

Indication

Investigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer.

Pharmacodynamic

Information currently not available.

Mechanism of action

ASA404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The proposed mechanism of action for ASA404 is directly increasing permeability of the tumor's endothelial cells. Vasoactive mediators such as tumor necrosis factor (TNF) may also be i... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vadimezan
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The metabolism of (R)-warfarin can be decreased when combined with Vadimezan.
6-O-benzylguanine
The metabolism of 6-O-benzylguanine can be decreased when combined with Vadimezan.
8-azaguanine
The metabolism of Vadimezan can be decreased when combined with 8-azaguanine.
8-chlorotheophylline
The metabolism of 8-chlorotheophylline can be decreased when combined with Vadimezan.
9-Deazaguanine
The metabolism of Vadimezan can be decreased when combined with 9-Deazaguanine.
9-Methylguanine
The metabolism of Vadimezan can be decreased when combined with 9-Methylguanine.
Abatacept
The metabolism of Vadimezan can be increased when combined with Abatacept.
Abiraterone
The serum concentration of Vadimezan can be increased when it is combined with Abiraterone.
Acefylline
The metabolism of Acefylline can be decreased when combined with Vadimezan.
Acenocoumarol
The metabolism of Vadimezan can be decreased when combined with Acenocoumarol.
Acetaminophen
The metabolism of Vadimezan can be decreased when combined with Acetaminophen.
Acyclovir
The metabolism of Vadimezan can be decreased when combined with Acyclovir.
Adalimumab
The metabolism of Vadimezan can be increased when combined with Adalimumab.
Afelimomab
The metabolism of Vadimezan can be increased when combined with Afelimomab.
Agomelatine
The metabolism of Agomelatine can be decreased when combined with Vadimezan.
Albendazole
The metabolism of Vadimezan can be decreased when combined with Albendazole.
Albinterferon Alfa-2B
The metabolism of Vadimezan can be decreased when combined with Albinterferon Alfa-2B.
Alosetron
The metabolism of Vadimezan can be decreased when combined with Alosetron.
Aminophenazone
The metabolism of Vadimezan can be decreased when combined with Aminophenazone.
Aminophylline
The metabolism of Vadimezan can be decreased when combined with Aminophylline.
3 References
  1. 1 . Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC: Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer. 2005 Aug 20;116(2):322-6.PubMed: 15800918
  2. 2 . McKeage MJ: The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs. 2008 Jan;17(1):23-9.PubMed: 18095916
  3. 3 . Link Link